Håkan Björklund is an operating executive at Avista Capital Partners. Mr. Björklund was retained by Avista Capital Partners in October 2011. Mr. Björklund is the former CEO of Nycomed, which was sold to Takeda Pharmaceuticals in September 2011 for 9.6 billion euros. Mr. Björklund worked closely with the Avista team on the development of Nycomed prior to its sale to Takeda. Under Mr. Björklund’s leadership, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America. In 2006, Mr. Björklund led the integration of Altana Pharmaceutical, a German-based company that was acquired by Nycomed for 4.2 billion euros. He was also instrumental in growing Nycomed in emerging markets, including through the acquisition of Guangdong Techpool Bio-Pharma Co., Ltd, a Chinese bio-pharmaceutical company, in 2010.
Prior to Nycomed, Mr. Björklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco. Mr. Björklund is Chairman of the Board of Directors at Acino International AG, Swedish Orphan Biovitrum AB and Trimb Holding AB and is a member of the Board of Directors of Alere Inc. and Coloplast A/S. Mr. Björklund was formerly Chairman of H. Lundbeck A/S and a Director at Atos Medical AB and Danisco A/S.
Mr. Björklund holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.